NCT00304590

Study of XL999 in Patients With Multiple Myeloma

A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Symphony Evolution, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	XL999	Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.

Timeline

• Start date: 2006-02-01
• Primary completion: 2006-12-01
• Completion: 2007-05-01
• First posted: 2006-03-20
• Last updated: 2010-02-22

Locations

3 sites across 1 country: United States